Vasopressin in the ICU

Current Opinion in Critical Care

Volumn 10, Issue 6, 2004, Pages 442-448

  Holmes, Cheryl L ^a,b   Walley, Keith R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b KELOWNA GENERAL HOSPITAL   (Canada)

Author keywords

CPR; Hemorrhagic shock; Sepsis syndrome; Septic shock; Vasopressins

Indexed keywords

ADRENALIN; AMIODARONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NORADRENALIN; OXYGEN; PHENYLEPHRINE; VASOPRESSIN;

CARDIOPULMONARY ARREST; CARDIOPULMONARY BYPASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL DISEASE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HEART RIGHT VENTRICLE FAILURE; HEMORRHAGIC SHOCK; HUMAN; INTENSIVE CARE UNIT; INTESTINE BLOOD FLOW; INTESTINE INFARCTION; KIDNEY BLOOD FLOW; KIDNEY FAILURE; LIMB ISCHEMIA; LIVER FAILURE; MENINGOCOCCOSIS; NONHUMAN; PERFUSION; REVIEW; SEPSIS; SEPTIC SHOCK; SKIN DEFECT; SPLANCHNIC BLOOD FLOW; STROKE; SURVIVAL; SYSTEMIC CIRCULATION; TACHYCARDIA; TREATMENT OUTCOME;

EID: 10244259158     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ccx.0000144769.19213.0c     Document Type: Review

References (33)

1. Landry DW, Oliver JA: The pathogenesis of vasodilatory shock. N Engl J Med 2001, 345:588-595. Vasodilatory shock results from the failure of vascular smooth muscle to constrict and is caused most often by sepsis. The mechanisms that underlie this failure including vasopressin deficiency, activation of potassium channels, and increased nitric oxide synthesis, are described in this review.
2. Holmes CL, Landry DW, Granton JT: Science review: vasopressin and the cardiovascular system part 1-receptor physiology. Crit Care 2003, 7:427-434. Unlike other vasoconstrictor agents, vasopressin also has vasodilatory properties. Knowledge of the function and distribution of vasopressin receptors is key to understanding the seemingly contradictory actions of vasopressin on the vascular system. Part one of this review discusses the vasopressin signaling pathways, distribution of vasopressin receptors, and the structural elements responsible for the functional diversity found within the vasopressin receptor family.
3. Holmes CL, Granton JT, Landry DW: Science review: vasopressin and the cardiovascular system part 2-clinical physiology. Crit Care 2004, 8:15-23. In part two of this review, the authors explore the mechanisms of vasoconstriction and vasodilation of the vascular smooth muscle with emphasis on vasopressin interaction in these pathways. They discuss seemingly contradictory studies and highlight some new information regarding the actions of vasopressin on the heart. Finally, they summarize the clinical trials of vasopressin in vasodilatory shock states and comment on areas for future research.
4. Sharshar T, Blanchard A, Paillard M, et al.: Circulating vasopressin levels in septic shock. Crit Care Med 2003, 31:1752-1758. This is the largest observational human study to demonstrate biphasic vasopressin levels in septic shock.
5. Rosenzweig EB, Starc TJ, Chen JM, et al.: Intravenous arginine-vasopressin in children with vasodilatory shock after cardiac surgery. Circulation 1999, 100(19 suppl):II182-II186.
6. Choi SJ, Jeffries HE, Willis BL, et al.: Vasopressin deficiency in pediatric septic shock. Pediatr Crit Care Med 2003, 4:A5.
7. Leclerc F, Walter-Nicolet E, Leteurtre S, et al.: Admission plasma vasopressin levels in children with meningococcal septic shock. Intensive Care Med 2003, 29:1339-1344. Vasopressin levels are high in pediatric meningococcal septic shock, leading to speculation that exogenous vasopressin may be of little use in this population.
8. Dünser MW, Mayr AJ, Ulmer H, et al.: Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 2003, 107:2313-2319. In the largest human randomized, controlled trial of low-dose vasopressin to date, 48 patients with catecholamine-resistant vasodilatory shock were prospectively randomized to receive a combined infusion of vasopressin and norepinephrine or norepinephrine infusion alone. The combination of vasopressin and norepinephrine proved to be superior to norepinephrine alone in terms of cardiac arrhythmias, cardiac output, mean arterial pressure, and gastrointestinal perfusion.
9. Morales DL, Garrido MJ, Madigan JD, et al.: A double-blind randomized trial: prophylactic vasopressin reduces hypotension after cardiopulmonary bypass. Ann Thorac Surg 2003, 75:926-930. In this double-blind trial of vasopressin versus placebo in patients on angiotensin-converting enzyme inhibitor therapy, prophylactic administration of vasopressin before cardiopulmonary bypass, reduced post-cardiopulmonary bypass hypotension and vasoconstrictor requirements and was associated with a shorter ICU stay.
10. Sun Q, Dimopoulos G, Nguyen DN, et al.: Low-dose vasopressin in the treatment of septic shock in sheep. Am J Respir Crit Care Med 2003, 168:481-486. This animal randomized, controlled trial demonstrates that low-dose vasopressin alone or in combination with norepinephrine is superior to norepinephrine alone in organ perfusion and survival.
11. Guzman JA, Rosado AE, Kruse JA: Vasopressin vs norepinephrine in endotoxic shock: systemic, renal, and splanchnic hemodynamic and oxygen transport effects. J Appl Physiol 2003, 95:803-809. This well-executed before and after animal study demonstrates the differential effects of vasopressin and norepinephrine on the splanchnic and renal circulations.
12. Levy B, Vallee C, Lauzier F, et al.: Comparative effects of vasopressin, norepinephrine, and L-canavanine, a selective inhibitor of inducible nitric oxide synthase, in endotoxic shock. Am J Physiol Heart Circ Physiol 2004, 287:H209-H215.
13. van Haren FM, Rozendaal FW, van der Hoeven JG: The effect of vasopressin on gastric perfusion in catecholamine-dependent patients in septic shock. Chest 2003, 124:2256-2260. This study demonstrates that vasopressin infusion of 0.04 U/min may induce gastric hypoperfusion.
14. Klinzing S, Simon M, Reinhart K, et al.: High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 2003, 31:2646-2650. This study demonstrates that vasopressin in doses that replace norepinephrine worsens global oxygen delivery and hepatosplanchnic blood flow in human septic shock.
15. Martikainen TJ, Tenhunen JJ, Uusaro A, et al.: The effects of vasopressin on systemic and splanchnic hemodynamics and metabolism in endotoxin shock. Anesth Analg 2003, 97:1756-1763.
16. Dünser MW, Mayr AJ, Tur A, et al.: Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med 2003, 31:1394-1398. This is the largest observational study to report the incidence of ischemic skin lesions in patients who received vasopressin for vasodilatory shock.
17. Westphal M, Stubbe H, Sielenkamper AW, et al.: Effects of titrated arginine vasopressin on hemodynamic variables and oxygen transport in healthy and endotoxemic sheep. Crit Care Med 2003, 31:1502-1508. This dose-response study demonstrated that high-dose but not low-dose vasopressin worsened oxygen delivery.
18. Holmes CL: Vasopressin in septic shock: does dose matter? Crit Care Med 2004, 32:1423-1424.
19. Malay MB, Ashton JL, Dahl K, et al.: Heterogeneity of the vasoconstrictor effect of vasopressin in septic shock. Crit Care Med 2004, 32:1327-1331. In this animal model of septic shock, moderately higher doses of vasopressin induced ischemia in the mesenteric and renal circulations. The data indicate that the safe dose range for exogenous vasopressin in septic shock is narrow and support the current practice of fixed low-dose administration, generally 0.04 U/min and in no case exceeding 0.1 U/min.
20. Dunser MW, Hasibeder WR, Wenzel V, et al.: Lessons learned from high-dosage vasopressin infusion in septic shock. Crit Care Med 2004, 32:1433-1434.
21. Stadlbauer KH, Wagner-Berger HG, Wenzel V, et al.: Survival with full neurologic recovery after prolonged cardiopulmonary resuscitation with a combination of vasopressin and epinephrine in pigs. Anesth Analg 2003, 96:1743-1749.
22. Krismer AC, Wenzel V, Voelckel WG, et al.: Effects of vasopressin on adrenal gland regional perfusion during experimental cardiopulmonary resuscitation. Resuscitation 2003, 56:223-228.
23. Schwarz B, Mair P, Wagner-Berger H, et al.: Neither vasopressin nor amiodarone improve CPR outcome in an animal model of hypothermic cardiac arrest. Acta Anaesthesiol Scand 2003, 47:1114-1118.
24. Wenzel V, Krismer AC, Arntz HR, et al.: A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. N Engl J Med 2004, 350:105-113. This is the largest human randomized, controlled trial of vasopressin versus epinephrine in survival from out-of-hospital cardiac arrest.
25. McIntyre KM: Vasopressin in asystolic cardiac arrest. N Engl J Med 2004, 350:179-181.
26. Nolan JP, Nadkarni V, Montgomery WH: Vasopressin versus epinephrine for cardiopulmonary resuscitation. N Engl J Med 2004, 350:2206-2209.
27. Alvarez GF, Bihari D: Vasopressin versus epinephrine for cardiopulmonary resuscitation. N Engl J Med 2004, 350:2206-2209.
28. Ballew KA: Vasopressin versus epinephrine for cardiopulmonary resuscitation. N Engl J Med 2004, 350:2206-2209.
29. Stern SA: Low-volume fluid resuscitation for presumed hemorrhagic shock: helpful or harmful? Curr Opin Crit Care 2001, 7:422-430.
30. Stadlbauer KH, Wagner-Berger HG, Raedler C, et al.: Vasopressin, but not fluid resuscitation, enhances survival in a liver trauma model with uncontrolled and otherwise lethal hemorrhagic shock in pigs. Anesthesiology 2003, 98:699-704.
31. Raedler C, Voelckel WG, Wenzel V, et al.: Treatment of uncontrolled hemorrhagic shock after liver trauma: fatal effects of fluid resuscitation versus improved outcome after vasopressin. Anesth Analg 2004, 98:1759-1766.
32. Voelckel WG, Raedler C, Wenzel V, et al.: Arginine vasopressin, but not epinephrine, improves survival in uncontrolled hemorrhagic shock after liver trauma in pigs. Crit Care Med 2003, 31:1160-1165. This animal randomized, controlled trial demonstrates a benefit of vasopressin over epinephrine in uncontrolled intraabdominal hemorrhage.
33. Dellinger RP, Carlet JM, Masur H, et al.: Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004, 32:858-873. This excellent document critically evaluates all currently accepted therapies of severe sepsis and septic shock and urges cautious use of vasopressin pending further studies.